JPRN-UMIN000012444招募中未知
Observational study of Pertuzumab in combination with Trastuzumab and Docetaxel in patients with metastatic HER2-positive breast cancer that have the history of Trastuzumab treatment - Observational study of Pertuzumab in patients with HER2-positive MBC with the history of Trastuzumab treatment
Osaka City University Graduate School of Medicine0 个研究点目标入组 20 人开始时间: 2013年11月29日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional,observational
入排标准
- 年龄范围
- 18years-old 至 80years-old（—）
- 性别
- Female
入选标准
- 未提供
排除标准
- •1. Male patients 2. Patients with allergy to the medicines in this protocol treatment. 3. Active infection or fever suspicious of infection. 4. Pregnant women, nursing mothers, women with possibility of pregnancy or women with no intention to contraception. 5. Other patients who were considered by the primary care physician to be inappropriate as subjects of this trial.
研究者
相似试验
已完成
不适用
A Randomized, Open Label Study to Compare the Complete Pathological Response Rate Achieved With 4 Combinations of Herceptin, Docetaxel and Pertuzumab in Patients With Locally Advanced, Inflammatory or Early Stage HER2 Positive Breast Cancer-C50 Malignant neoplasm of breastMalignant neoplasm of breastC50PER-121-08PRODUCTOS ROCHE Q.F.S.A.,9
进行中（未招募）
1 期
A randomized phase II trial of pertuzumab in combination with trastuzumab with or without chemotherapy, both followed by T-DM1 in case of progression, in patients with HER2-positive metastatic breast cancer - PERNETTAEUCTR2012-002556-17-FRICANCER208
已完成
2 期
A randomized phase II trial of pertuzumab in combination with trastuzumab with or without chemotherapy, both followed by T-DM1 in case of progression, in patients with HER2-positive metastatic breast cancer10006291Breast cancerNL-OMON44863ICANCER26
进行中（未招募）
1 期
_EUCTR2012-002556-17-DEICANCER208
进行中（未招募）
1 期
A randomized phase II trial of pertuzumab in combination with trastuzumab with or without chemotherapy, both followed by T-DM1 in case of progression, in patients with HER2-positive metastatic breast cancer - PERNETTAHER2-positive metastatic breast cancerMedDRA version: 19.1Level: PTClassification code 10006187Term: Breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2012-002556-17-NLICANCER208